Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Antibody drug conjugate (ADC) | 1 |
Top 5 Target | Count |
---|---|
CD33 x DNA | 1 |
Target |
Mechanism CD33 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date17 May 2000 |
Target |
Mechanism GD2 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Microbiome modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Gemtuzumab Ozogamicin ( CD33 x DNA ) | Acute Myeloid Leukemia More | Phase 3 |
Allogeneic anti-GD2 CAR-T (Baylor College of Medicine) ( GD2 ) | Neuroblastoma recurrent More | Pending |
Fecal Microbiota Transplantation(The Children's Mercy Hospital) | Colitis, Ulcerative More | Pending |